AngioDynamics: HC Wainwright Raises Buy Rating, PT Boosted to $16

AngioDynamics: HC Wainwright Raises Buy Rating, PT Boosted to $16

AngioDynamics Inc. (NASDAQ:ANGO) received a boost from H.C. Wainwright & Co. Inc., which raised its buy rating and increased its price target to $16, up from $15, according to a research note released on Monday, April 7th [1]. The research firm's positive outlook is driven by the company's strong financial performance and strategic transformation, particularly in the medical technology (Med Tech) sector.

James C. Clemmer, CEO of AngioDynamics, highlighted the company's robust growth during the latest earnings call. Total revenue for the quarter ending March 31, 2025, was $80.2 million, representing a 12% year-over-year increase, led by Med Tech growth of over 20% and Med Device growth of more than 6% [2]. The company's strategic transformation is evident in its focus on cost management and operational efficiency, which has resulted in a 14% operating margin [3].

The Q4 2025 earnings report, released on July 15, 2025, showed mixed market impact but presented a nuanced picture of short-term uncertainty and medium-term recovery potential. The company's net income aligned with continuing operations, with operating expenses remaining disciplined relative to revenue. The report also highlighted the company's ability to manage debt levels, reducing financial stress [3].

AngioDynamics has also updated its FY 2026 earnings guidance, with EPS guidance of -$0.350 to -$0.250 and revenue guidance of $305.0 million to $310.0 million, compared to the consensus estimates of -$0.227 and $304.9 million, respectively [4]. The company's stock performance has been relatively stable, with a 52-week low of $5.82 and a 52-week high of $13.50 [4].

The increase in the buy rating and price target by H.C. Wainwright reflects the market's positive sentiment towards AngioDynamics' strategic transformation and strong financial performance. Investors should closely monitor the company's guidance updates and competitive landscape shifts to refine their positioning. While the stock shows potential for medium-term gains, investors must weigh this against the sector's historical indifference to earnings misses.

References:
[1] https://www.investing.com/news/analyst-ratings/biomx-stock-maintains-buy-rating-at-hc-wainwright-with-15-price-target-93CH-4135224
[2] https://seekingalpha.com/news/4467571-angiodynamics-projects-305m-310m-fy26-sales-as-med-tech-drives-double-digit-growth
[3] https://www.ainvest.com/news/angiodynamics-q4-2025-earnings-release-mixed-market-impact-strategic-implications-2507/
[4] https://www.marketbeat.com/instant-alerts/angiodynamics-nasdaqango-releases-fy-2026-earnings-guidance-2025-07-15/